Oppenheimer Issues Positive Forecast for Astria Therapeutics (NASDAQ:ATXS) Stock Price

Astria Therapeutics (NASDAQ:ATXS) had its price objective upped by Oppenheimer from $26.00 to $28.00 in a report published on Thursday morning,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. TD Cowen initiated coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target on the stock. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Stock Down 7.1 %

Astria Therapeutics stock opened at $9.37 on Thursday. The stock has a 50-day moving average price of $11.40 and a 200 day moving average price of $10.62. The company has a market capitalization of $528.75 million, a price-to-earnings ratio of -4.48 and a beta of 0.71. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently modified their holdings of the company. Quest Partners LLC increased its stake in shares of Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. increased its position in shares of Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after buying an additional 2,861 shares in the last quarter. PDT Partners LLC purchased a new stake in shares of Astria Therapeutics in the third quarter valued at approximately $140,000. SG Americas Securities LLC acquired a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $155,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Astria Therapeutics during the 2nd quarter valued at approximately $171,000. 98.98% of the stock is owned by hedge funds and other institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.